♟️ Friday 27 February 2026 Fri, 27 Feb 2026

Rivco Australia has reported a remarkable 135% increase in net profit for the year ended 31 December 2025, alongside fully franked dividends and a solid net asset value per share.

Memphasys Limited has advanced its Felix™ System commercial rollout with key regulatory approvals and new international contracts, while trimming operating costs and narrowing losses in the first half of FY2026.

Rectifier Technologies Ltd reported a 61% plunge in revenue for H1 2026, resulting in a $2.35 million loss amid a softening EV charging market. The company is pushing forward with new product prototypes and exploring clean energy opportunities.

Future Generation Global Limited reported a 50% drop in net profit for 2025 but maintained strong investment portfolio growth and declared a special fully franked dividend, while continuing its significant social impact contributions.

Mayfield Group Holdings Ltd has reported a striking 52.8% increase in revenue and a 127.6% jump in profit for the half-year ending December 2025, driven by manufacturing growth and strategic acquisitions.

Elanor Investors Group reported a $24.5 million net loss for the half year to December 2024, grappling with debt covenant breaches and defaults. The group has struck a $125 million recapitalisation agreement with Rockworth Capital Partners to stabilise its balance sheet and pursue growth.

Yowie Group Limited reported a steep 752% increase in its half-year loss to US$4.66 million, amid governance upheaval and impaired loans to its majority shareholder. The company faces ongoing legal and regulatory challenges while pursuing a turnaround.

Clarity Pharmaceuticals has reported a steep 136% increase in its half-year loss to $55.6 million, alongside the closure of its European subsidiary, signaling a challenging period for the ASX-listed biotech.

Ainsworth Game Technology reported a 10% revenue increase to AUD 290.8 million for 2025 but posted a net loss of AUD 19.2 million, driven by a significant goodwill impairment and foreign currency headwinds. The company’s strategic investments and market challenges set the stage for a pivotal year ahead.

Metro Mining has delivered a remarkable turnaround in 2025, posting record shipments and profits, while announcing a strategic share buy-back and debt extension to underpin future growth.

Austral Gold Limited has reported a return to profitability in FY25, driven by the reopening of its Casposo Mine and a significant increase in gold equivalent production. The company also strengthened its balance sheet through a successful private placement and equity investments.

Actinogen Medical has successfully completed a $16.8 million capital raising, combining a $12 million placement with a $4.8 million share purchase plan, to fund its pivotal Alzheimer’s disease trial and other 2026 initiatives.

Future Generation Australia Limited reported robust financial results for 2025, with a 14.1% investment portfolio gain and a raised fully franked dividend, while continuing its commitment to social impact funding for vulnerable children.

Raiz Invest Limited reported a robust half-year performance for the period ending 31 December 2025, with revenue climbing 23.9% and a return to profitability driven by increased customer engagement and funds under management.

Structural Monitoring Systems PLC reported a 31% revenue increase to AUD 16.5 million for H1 2025, driven by strong avionics growth and improved profitability despite ongoing litigation and leadership changes.

Anteris Technologies Global Corp. posted a $94.2 million loss for 2025 amid a 29% revenue decline, while progressing its pivotal DurAVR THV clinical trial and securing $320 million in early 2026 financings.

Catalyst Metals Limited delivered a robust half-year result with revenues up 50% and profits rising 40%, driven by higher gold prices and operational advances including a doubling of reserves in the Plutonic Gold Belt.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

Entropy Neurodynamics reports a 14.8% reduction in half-year losses while progressing a pioneering clinical trial for Binge Eating Disorder using its proprietary psychedelic drug TRP-8803. The company also secured $6.1 million in new funding and strategic collaborations to enhance its neuropsychiatry platform.

Harvey Norman Holdings Limited reported a robust 6.9% rise in system sales revenue for 1H26, underpinned by strong Australian franchisee performance and overseas expansion. Profit before tax climbed 16.5%, boosted by property revaluations and disciplined cost management.

Mach7 Technologies reported a 23% drop in revenue to $13.65 million for H1 FY26, alongside a sharp increase in net loss to $5.75 million, as it embarks on a strategic commercial reset and expands its Asia-based engineering capabilities.

4DMedical Limited’s half-year report reveals rapid commercial traction following FDA clearance of its CT:VQ™ imaging technology, alongside a $150 million institutional placement that bolsters its cash reserves for global expansion.

Novatti Group Limited has reported a striking turnaround to a $3.8 million profit in the first half of 2026, despite a 42% drop in revenue. The fintech’s strategic divestments and reclassification of its AUDC investment signal a pivotal shift in its growth trajectory.

Mesoblast Limited reported its first commercial sales of FDA-approved Ryoncil, generating $48.7 million in net product sales for the half-year ended December 31, 2025, while reducing its net loss by 16%. The company also secured a $125 million five-year credit facility, restructuring its debt to support ongoing commercialization and development.